跳至主要内容
临床试验/NCT05961852
NCT05961852已完成1 期

COmbiNing Cutting and Drug-Eluting Balloon for Resistant Arteriovenous Fistula sTenOsis (CONCERTO)

Singapore General Hospital2 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2018年8月15日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
19
试验地点
2
主要终点
Target lesion primary patency

研究概览

简要总结

To evaluate the preliminary efficacy of combination of cutting and drug-coated balloon for the treatment of resistant AVF stenosis.

详细描述

This is a single arm pilot study recruiting 19 participants with resistant AVF stenosis (defined as having > 30% residual stenosis after optimal balloon angioplasty) to receive cutting and drug-coated balloon.

The outcome measure is target lesion primary patency at 6 months. Outcome will be clinically driven.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Failing mature upper limb AVF
  • Resistant stenosis (>30% residual stenosis) after optimal conventional balloon angioplasty (appropriately sized balloon, inflated up to rated burst pressure, at least twice for at least a minute per inflation)
  • Patient is >= 21 years of age
  • Ability to provide informed consent

排除标准

  • Thrombosed AVF
  • Target lesion has a sharp angle (> 45 degrees)
  • Lesions requiring cutting balloon size > 7 mm
  • Coagulopathy or thrombocytopaenia that cannot be adequately managed for the procedure
  • Contraindication to dual antiplatelet therapy
  • Severe allergy to contrast media that cannot be adequately managed for the procedure
  • Breast-feeding and/or pregnant females
  • Male patients who are planning to father children during the trial period
  • Unable to comply with follow up protocol (for instance, limited life expectancy)

结局指标

主要结局

Target lesion primary patency

时间窗: 6 months after index procedure

Time from index treatment to repeat treatment of target lesion or thrombosis of circuit.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验